Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility

Nucleic Acid Therapeutics

Volumn 28, Issue 3, 2018, Pages 146-157

  Kulkarni, Jayesh A ^a   Cullis, Pieter R ^a   Van Der Meel, Roy ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

drug delivery; gene therapy; genetic drugs; ionizable cationic lipid; lipid nanoparticle; nucleic acid

Indexed keywords

ALCOHOL; ALN TTR 02; ALN VSP 02; ARB 001467; ATU 027; BMS 986263; INCLISIRAN; JVRS 100; LIPID NANOPARTICLE; LIPOPLEX; MCRORNA 1325; MCRORNA 1388; MCRORNA 1440; MCRORNA 1647; MCRORNA 1851; MCRORNA 2416; MCRORNA 4157; MESSENGER RNA; MTL CEBPA; NANOPARTICLE; ND L 02S 0201; NUCLEIC ACID; PATISIRAN; PREXIGEBERSEN; SGT 53; SIRNA EPHA 2DOPC; SMALL INTERFERING RNA; TKM 080301; UNCLASSIFIED DRUG; VAL 181388; VAL 339851; VAL 506440; CATION; LIPID;

ADSORPTION; ARTICLE; CHEMICAL MODIFICATION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; GENE EDITING; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; INNATE IMMUNITY; LIVER CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); FAMILIAL AMYLOID POLYNEUROPATHY; GENE THERAPY; GENE TRANSFER; GENETICS; HYPERCHOLESTEROLEMIA; LIVER; MELANOMA; METABOLISM; PATHOLOGY; PROCEDURES; SKIN TUMOR; VIROLOGY; VIRUS INFECTION;

AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; CATIONS; CLINICAL TRIALS AS TOPIC; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; LIVER; MELANOMA; NANOPARTICLES; RNA, SMALL INTERFERING; SKIN NEOPLASMS; VIRUS DISEASES;

EID: 85048371018     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2018.0721     Document Type: Article

References (86)

1. Cullis PR and MJ Hope. (2017). Lipid nanoparticle systems for enabling gene therapies. Mol Ther 25:1467-1475.
2. Hajj KA and KA Whitehead. (2017). Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater 2:17056.
3. Kanasty R, JR Dorkin, A Vegas and D Anderson. (2013). Deliverymaterials for siRNAtherapeutics. NatMater 12:967.
4. Kotterman MA and DV Schaffer. (2014). Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet 15:445-451.
5. Liu C, L Zhang, H Liu and K Cheng. (2017). Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release 266:17-26.
6. Alnylam® Pharmaceuticals, Inc. (2017). In Media, A. (ed.). BusinessWire, www.businesswire.com/news/home/20170920005628/en Accessed January 11, 2018.
7. Jayaraman M, SM Ansell, BL Mui, YK Tam, J Chen, X Du, D Butler, L Eltepu, S Matsuda, et al. (2012). Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem Int Ed Engl 51:8529-8533.
8. Semple SC, A Akinc, J Chen, AP Sandhu, BL Mui, CK Cho, DW Sah, D Stebbing, EJ Crosley, et al. (2010). Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28:172-176.
9. Alnylam® Pharmaceuticals, Inc. (2017). http://investors.alnylam.com/news-releases/news-release-details/alnylamand-sanofi-present-positive-complete-results-apollo Accessed January 11, 2018.
10. Alnylam® Pharmaceuticals, Inc. (2017). http://investors.alnylam.com/news-releases/news-release-details/alnylamcompletes-submission-new-drug-application-us-food-and
11. Alnylam® Pharmaceuticals, Inc. (2018). http://investors.alnylam.com/news-releases/news-release-details/alnylamannounces-ema-acceptance-marketing-authorisation
12. Allen TM and PR Cullis. (2013). Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65:36-48.
13. Kawabata K, Y Takakura and M Hashida. (1995). The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm Res 12:825-830.
14. Judge AD, V Sood, JR Shaw, D Fang, K McClintock and I MacLachlan. (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23:457-462.
15. Layzer JM, AP McCaffrey, AK Tanner, Z Huang, MA Kay and BA Sullenger. (2004). In vivo activity of nucleaseresistant siRNAs. RNA 10:766-771.
16. Choi HS, W Liu, P Misra, E Tanaka, JP Zimmer, B Itty Ipe, MG Bawendi and JV Frangioni. (2007). Renal clearance of quantum dots. Nat Biotechnol 25:1165-1170.
17. Choi HS, W Liu, F Liu, K Nasr, P Misra, MG Bawendi and JV Frangioni. (2009). Design considerations for tumourtargeted nanoparticles. Nat Nanotechnol 5:42.
18. Geary RS, TA Watanabe, L Truong, S Freier, EA Lesnik, NB Sioufi, H Sasmor, M Manoharan and AA Levin. (2001). Pharmacokinetic properties of 2′-O-(2-methoxyethyl)- modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 296:890-897.
19. Sands H, LJ Gorey-Feret, AJ Cocuzza, FW Hobbs, D Chidester and GL Trainor. (1994). Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 45:932-943.
20. Shen X and DR Corey. (2018). Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 46:1584-1600.
21. Mirzayans R, MV Middlestadt and MC Paterson. (1992). Cytotoxic and mutagenic effects of methylnitrosourea in two human fetal fibroblast strains differing in O6- methylguanine-DNA methyltransferase activity. Carcinogenesis 13:1185-1190.
22. Capecchi MR. (1980). High efficiency transformation by direct microinjection of DNA into cultured mammalian cells. Cell 22:479-488.
23. Felgner PL, TR Gadek, M Holm, R Roman, HW Chan, M Wenz, JP Northrop, GM Ringold and M Danielsen. (1987). Lipofection: a highly efficient, lipid-mediated DNAtransfection procedure. Proc Natl Acad Sci U S A 84:7413-7417.
24. Ernsting MJ, M Murakami, A Roy and SD Li. (2013). Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release 172:782-794.
25. Fraley R, S Subramani, P Berg and D Papahadjopoulos. (1980). Introduction of liposome-encapsulated SV40 DNA into cells. J Biol Chem 255:10431-10435.
26. Fraley R, RM Straubinger, G Rule, EL Springer and D Papahadjopoulos. (1981). Liposome-mediated delivery of deoxyribonucleic acid to cells: enhanced efficiency of delivery related to lipid composition and incubation conditions. Biochemistry 20:6978-6987.
27. Filion MC and NC Phillips. (1997). Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1329:345-356.
28. Lappalainen K, I Jaaskelainen, K Syrjanen, A Urtti and S Syrjanen. (1994). Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res 11:1127-1131.
29. Wheeler JJ, L Palmer, M Ossanlou, I MacLachlan, RW Graham, YP Zhang, MJ Hope, P Scherrer and PR Cullis. (1999). Stabilized plasmid-lipid particles: construction and characterization. Gene Ther 6:271-281.
30. Fenske DB, I MacLachlan and PR Cullis. (2002). Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol 346:36-71.
31. Tam P, M Monck, D Lee, O Ludkovski, EC Leng, K Clow, H Stark, P Scherrer, RW Graham and PR Cullis. (2000). Stabilized plasmid-lipid particles for systemic gene therapy. Gene Ther 7:1867.
32. Ambegia E, S Ansell, P Cullis, J Heyes, L Palmer and I MacLachlan. (2005). Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta 1669:155-163.
33. Hafez IM, N Maurer and PR Cullis. (2001). On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther 8:1188-1196.
34. Aramaki Y, S Takano and S Tsuchiya. (1999). Induction of apoptosis in macrophages by cationic liposomes. FEBS Lett 460:472-476.
35. Dokka S, D Toledo, X Shi, V Castranova and Y Rojanasakul. (2000). Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res 17:521-525.
36. Yan W, W Chen and L Huang. (2008). Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J Control Release 130:22-28.
37. Bailey AL and PR Cullis. (1994). Modulation of membrane fusion by asymmetric transbilayer distributions of amino lipids. Biochemistry 33:12573-12580.
38. Semple SC, SK Klimuk, TO Harasym, N Dos Santos, SM Ansell, KF Wong, N Maurer, H Stark, PR Cullis, et al. (2001). Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 1510:152-166.
39. Maurer N, KF Wong, H Stark, L Louie, D McIntosh, T Wong, P Scherrer, SC Semple and PR Cullis. (2001). Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J 80:2310-2326.
40. Jeffs LB, LR Palmer, EG Ambegia, C Giesbrecht, S Ewanick and I MacLachlan. (2005). A scalable, extrusionfree method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 22:362-372.
41. Batzri S and ED Korn. (1973). Single bilayer liposomes prepared without sonication. Biochim Biophys Acta 298: 1015-1019.
42. Hirota S, CT de Ilarduya, LG Barron and FC Szoka, Jr. (1999). Simple mixing device to reproducibly prepare cationic lipid-DNA complexes (lipoplexes). Biotechniques 27:286-290.
43. Belliveau NM, J Huft, PJ Lin, S Chen, AK Leung, TJ Leaver, AW Wild, JB Lee, RJ Taylor, et al. (2012). Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol Ther Nucleic Acids 1:e37.
44. Evers MJW, JA Kulkarni, R van der Meel, PR Cullis, P Vader and RM Schiffelers. (2018). State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery. Small Methods Submitted.
45. de Jong S, G Chikh, L Sekirov, S Raney, S Semple, S Klimuk, N Yuan, M Hope, P Cullis and Y Tam. (2007). Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol Immunother 56:1251-1264.
46. Raney SG, KD Wilson, L Sekirov, G Chikh, SD de Jong, PR Cullis and YK Tam. (2008). The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN. J Drug Target 16:564-577.
47. Wilson KD, SG Raney, L Sekirov, G Chikh, SD deJong, PR Cullis and YK Tam. (2007). Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int Immunopharmacol 7:1064-1075.
48. Zimmermann TS, ACH Lee, A Akinc, B Bramlage, D Bumcrot, MN Fedoruk, J Harborth, JA Heyes, LB Jeffs, et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441:111.
49. Tam YY, S Chen and PR Cullis. (2013). Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics 5:498-507.
50. Judge A, K McClintock, JR Phelps and I Maclachlan. (2006). Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 13:328-337.
51. Ellens H, J Bentz and FC Szoka. (1985). H+- and Ca2+- induced fusion and destabilization of liposomes. Biochemistry 24:3099-3106.
52. Cullis PR and MJ Hope. (1978). Effects of fusogenic agent on membrane structure of erythrocyte ghosts and the mechanism of membrane fusion. Nature 271:672.
53. Cullis PR and B de Kruijff. (1978). The polymorphic phase behaviour of phosphatidylethanolamines of natural and synthetic origin. A 31P NMR study. Biochim Biophys Acta 513: 31-42.
54. Gruner SM, PR Cullis, MJ Hope and CP Tilcock. (1985). Lipid polymorphism: the molecular basis of nonbilayer phases. Annu Rev Biophys Biophys Chem 14:211-238.
55. Butler JS, A Chan, S Costelha, S Fishman, JL Willoughby, TD Borland, S Milstein, DJ Foster, P Goncalves, et al. (2016). Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid 23:109-118.
56. Alnylam® Pharmaceuticals. I. (2012). http://investors.alnylam.com/news-releases/news-release-details/alnylaminitiates-phase-i-clinical-study-aln-ttr02-rnai Accessed March 14, 2018.
57. Coelho T, D Adams, A Silva, P Lozeron, PN Hawkins, T Mant, J Perez, J Chiesa, S Warrington, et al. (2013). Safety and efficacy of RNAi therapy for transthyretin amyloidosis. New Engl J Med 369:819-829.
58. Suhr OB, T Coelho, J Buades, J Pouget, I Conceicao, J Berk, H Schmidt, M Waddington-Cruz, JM Campistol, et al. (2015). Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 10:109.
59. Szebeni J, F Muggia, A Gabizon and Y Barenholz. (2011). Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 63:1020-1030.
60. Leung AK, IM Hafez, S Baoukina, NM Belliveau, IV Zhigaltsev, E Afshinmanesh, DP Tieleman, CL Hansen, MJ Hope and PR Cullis. (2012). Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core. J Phys Chem C Nanomater Interfaces 116:18440-18450.
61. Leung AK, YY Tam, S Chen, IM Hafez and PR Cullis. (2015). Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems. J Phys Chem B 119:8698-8706.
62. Yan X, F Kuipers, LM Havekes, R Havinga, B Dontje, K Poelstra, GL Scherphof and JA Kamps. (2005). The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem Biophys Res Commun 328:57-62.
63. Akinc A, W Querbes, S De, J Qin, M Frank-Kamenetsky, KN Jayaprakash, M Jayaraman, KG Rajeev, WL Cantley, et al. (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18:1357-1364.
64. Chen S, YYC Tam, PJC Lin, MMH Sung, YK Tam and PR Cullis. (2016). Influence of particle Size on the in vivo potency of lipid nanoparticle formulations of siRNA. J Control Release 235:236-244.
65. Fitzgerald K, S White, A Borodovsky, BR Bettencourt, A Strahs, V Clausen, P Wijngaard, JD Horton, J Taubel, et al. (2017). A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 376:41-51.
66. Harvie P, FMP Wong and MB Bally. (2000). Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci 89:652-663.
67. Song LY, QF Ahkong, Q Rong, Z Wang, S Ansell, MJ Hope and B Mui. (2002). Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim Biophys Acta 1558:1-13.
68. Lee JB, KZhang, YY Tam, J Quick, YK Tam, PJ Lin, S Chen, Y Liu, JK Nair, et al. (2016). A Glu-urea-Lys ligand-conjugated lipid nanoparticle/siRNA system inhibits androgen receptor expression in vivo. Mol Ther Nucleic Acids 5:e348.
69. Yamamoto Y, PJ Lin, E Beraldi, F Zhang, Y Kawai, J Leong, H Katsumi, L Fazli, R Fraser, et al. (2015). siRNA lipid nanoparticle potently silences clusterin and delays progression when combined with androgen receptor cotargeting in enzalutamide-resistant prostate cancer. Clin Cancer Res 21:4845-4855.
70. Vance JE and H Hayashi. (2010). Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta 1801:806-818.
71. Rungta RL, HB Choi, PJ Lin, RW Ko, D Ashby, J Nair, M Manoharan, PR Cullis and BA Macvicar. (2013). Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain. Mol Ther Nucleic Acids 2:e136.
72. Rungta RL, HB Choi, JR Tyson, A Malik, L Dissing- Olesen, PJC Lin, SM Cain, PR Cullis, TP Snutch and BA MacVicar. (2015). The cellular mechanisms of neuronal swelling underlying cytotoxic edema. Cell 161:610-621.
73. Kulkarni JA, YYC Tam, S Chen, J Zaifman, YK Tam, PR Cullis and S Biswas. (2017). Rapid synthesis of lipid nanoparticles containing hydrophobic inorganic nanoparticles. Nanoscale 9:13600-13609.
74. Acuitas Therapeutics. (2018). https://acuitastx.com/portfoliotype/lipid-nanoparticles Accessed January 11, 2018.
75. Thess A, S Grund, BL Mui, MJ Hope, P Baumhof, M Fotin-Mleczek and T Schlake. (2015). Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther 23: 1456-1464.
76. Pardi N, AJ Secreto, X Shan, F Debonera, J Glover, Y Yi, H Muramatsu, H Ni, BL Mui, et al. (2017). Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun 8:14630.
77. Pardi N, S Tuyishime, H Muramatsu, K Kariko, BL Mui, YK Tam, TD Madden, MJ Hope and D Weissman. (2015). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release 217:345-351.
78. Pardi N, MJ Hogan, FW Porter and D Weissman. (2018). mRNA vaccines - A new era in vaccinology. Nat Rev Drug Discov [Epub ahead of print]; DOI: 10.1038/nrd.2017.243.
79. Lutz J, S Lazzaro, M Habbeddine, KE Schmidt, P Baumhof, BL Mui, YK Tam, TD Madden, MJ Hope, et al. (2017). Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2:29.
80. Pardi N, MJ Hogan, RS Pelc, H Muramatsu, H Andersen, CR DeMaso, KA Dowd, LL Sutherland, RM Scearce, et al. (2017). Zika virus protection by a single low-dose nucleosidemodified mRNA vaccination. Nature 543:248.
81. Kranz LM, M Diken, H Haas, S Kreiter, C Loquai, KC Reuter, M Meng, D Fritz, F Vascotto, et al. (2016). Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534:396-401.
82. Kulkarni JA, JL Myhre, S Chen, YYC Tam, A Danescu, JM Richman and PR Cullis. (2016). Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. Nanomedicine 13:1377-1387.
83. Singh V, D Braddick and PK Dhar. (2017). Exploring the potential of genome editing CRISPR-Cas9 technology. Gene 599:1-18.
84. Schaefer KA, WH Wu, DF Colgan, SH Tsang, AG Bassuk and VB Mahajan. (2017). Unexpected mutations after CRISPR-Cas9 editing in vivo. Nat Methods 14:547-548.
85. Yin H, CQ Song, S Suresh, Q Wu, S Walsh, LH Rhym, E Mintzer, MF Bolukbasi, LJ Zhu, et al. (2017). Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol 35:1179-1187.
86. Finn JD, AR Smith, MC Patel, L Shaw, MR Youniss, J van Heteren, T Dirstine, C Ciullo, R Lescarbeau, et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep 22: 2227-2235.